CFGS
CHRS icon

Concourse Financial Group Securities’s Coherus Oncology CHRS Stock Holding History

Concourse Financial Group Securities’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-135
Closed -$2.29K – 2098
2020
Q1 		$2K Buy
135
+14
+12% +$259 ﹤0.01% 1864
2019
Q4 		$2K Buy
+121
New +$2.23K ﹤0.01% 1872

Other funds holding CHRS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Concourse Financial Group Securities's CHRS Position: Q2 2020 in Review

Concourse Financial Group Securities sold out of Coherus Oncology (CHRS) in Q2 2020, closing a stake of 135 shares — an estimated $2.29K sold.

Concourse Financial Group Securities first reported a position in CHRS in Q4 2019 and held it in 2 quarters. The position peaked at $2K in Q1 2020. 188 funds tracked by Wall St. Rank hold CHRS as of Q2 2020.

  • Concourse Financial Group Securities reported no remaining Coherus Oncology position as of Q2 2020 after selling out during the quarter.
  • Concourse Financial Group Securities sold 135 Coherus Oncology shares in Q2 2020, an estimated $2.29K.
  • Concourse Financial Group Securities first reported a position in Coherus Oncology in Q4 2019 and held it in 2 quarters.
  • Concourse Financial Group Securities's Coherus Oncology position peaked at $2K in Q1 2020.
  • 188 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2020.

Based on Concourse Financial Group Securities's 13F filing for Q2 2020, filed 13 Aug 2020.